

93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: May 17, 2023.

David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10897 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Environmental Health Sciences Council.

This will be a hybrid meeting held in-person and virtually and will be open to the public as indicated below. Individuals who plan to attend in-person or view the virtual meeting and need special assistance or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting can be accessed from the NIH Videocast at the following link: <https://www.niehs.nih.gov/news/webcasts/index.cfm>.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Environmental Health Sciences Council, National Advisory Environmental Health Sciences Council (NAEHSC).

Date: June 6–7, 2023.

Open: June 6, 2023, 10:00 a.m. to 3:00 p.m.

Agenda: Call to Order, Report of the Director, Hypothetical Interventions to Reduce Racial and Ethnic Disparities in Phthalate Exposure and the Impact on Preterm Birth, and CSR's Initiatives to Strengthen Peer Review.

Place: NIEHS/National Institutes of Health, 111 TW Alexander Drive, Research Triangle Park, NC 27709, (Hybrid Meeting).

Closed: June 6, 2023, 3:15 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications and/or proposals.

Place: NIEHS/National Institutes of Health, 111 TW Alexander Drive, Research Triangle Park, NC 27709,

Open: June 7, 2023, 10:00 a.m. to 3:45 p.m.

Agenda: Invited Speakers, NIEHS REEP, and DEIA Council Workgroup.

Place: NIEHS/National Institutes of Health, 111 TW Alexander Drive, Research Triangle Park, NC 27709, (Hybrid Meeting).

Contact Person: David M. Balshaw, BA, Ph.D., Acting Director and Chief, Division of Extramural Research and Training, National Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–27, Research Triangle Park, NC 27709–2233, 984–287–3234, balshaw@niehs.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has stringent procedures for entrance into NIH federal property. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's home page: <https://www.niehs.nih.gov/about/boards/naehsc/index.cfm>, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: May 17, 2023.

Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10895 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Aging; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material,

and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Aging Special Emphasis Panel; P01 Mitochondrial Mechanisms of Aging.

Date: July 6, 2023.

Time: 11:30 a.m. to 4:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, National Institute on Aging, Gateway Building, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Ivan Tadeu Rebutini, Ph.D. Scientific Review Officer, National Institute on Aging, National Institutes of Health, 7201 Wisconsin Avenue, Bethesda, MD 20892, (301) 496–2879, Ivan.rebutini@niehs.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS)

Dated: May 17, 2023.

Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023–10899 Filed 5–22–23; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; Social Drivers of Mental Illnesses in Low and Middle Income Countries.

Date: June 22, 2023.

Time: 11:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Claudio Dario Ortiz, Ph.D., Scientific Review Officer, Division of

Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Rockville, MD 20892, 305-586-9937, claudio.ortiz@nih.gov.

Name of Committee: National Institute of Mental Health Special Emphasis Panel; BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00).

Date: June 22, 2023.

Time: 11:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Emma Perez-Costas, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Rockville, MD 20892, 301-827-9275, emma.perez-costas@nih.gov.

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: May 17, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-10930 Filed 5-22-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Amend Notice of Meeting

Notice is hereby given of a change in the meeting of the National Heart, Lung, and Blood Institute Special Emphasis Panel, June 6, 2023, 1 p.m. to 5 p.m., National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD, 20892 which was published in the **Federal Register** on May 15, 2023, FR Document No. 2023-10224, 88 FRN 30997.

This notice is being amended to correct the June 6, 2023 meeting title that was published as "The National Heart, Lung, and Blood Institute Special Emphasis Panel SPECIAL EMPHASIS PANEL". The correct title is "The National Heart, Lung, and Blood Institute Special Emphasis Panel NRSA Member Conflict Panel". The meeting is closed to the public.

Dated: May 18, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-10936 Filed 5-22-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information on the Prioritization of Drug, Vaccine, and Dietary Supplement Research Needs for Pregnant, Postpartum, and Lactating Persons

AGENCY: National Institutes of Health, HHS.

ACTION: Request for information.

SUMMARY: The National Institute of Child Health and Human Development (NICHD) seeks nominations for drug, vaccine, and dietary supplement research needs to be considered in the development of a Priority List of Drug, Vaccine, and Dietary Supplement Research Needs for Pregnant, Postpartum, and Lactating Persons. The NICHD is gathering nominations for drugs prescribed for conditions specific to or that co-occur during pregnancy and the postpartum period, including for lactation; dietary supplements that may be used in preparation for, during, or after pregnancy; and vaccines used by pregnant or lactating persons to prevent or treat disease. Additionally, the NICHD is seeking information on factors and processes it could consider in prioritizing these nominations. Nominations are requested from public and private stakeholders such as, but not limited to, researchers, academia, small- and large-scale industries, non-profit organizations, patients, providers, advocacy groups, payors, and federal agencies.

DATES: The request for information is open for public comment and will be accepted through September 29, 2023.

ADDRESSES: Submissions must be submitted via a survey using the following link: <https://www.surveymonkey.com/r/PRGLAC23>.

FOR FURTHER INFORMATION CONTACT: Questions about this request for information should be directed to Camille Fabiyi, Ph.D., MPH, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, 6710B Rockledge Dr., Bethesda, MD 20892, NICHD-PRGLAC@mail.nih.gov, 301-496-3916.

SUPPLEMENTARY INFORMATION: This RFI is intended to obtain information to help advance recommendations outlined in the 2018 Report of the Task Force for Research Specific to Pregnant and Lactating Women (PRGLAC) and 2020 PRGLAC Implementation Plan. In 2016, Congress established PRGLAC through

the 21st Century Cures Act to advise the Secretary of Health and Human Services (HHS) regarding gaps in knowledge and research on safe and effective therapies for pregnant and lactating persons. The PRGLAC task force was charged with providing advice and guidance to the HHS Secretary on activities related to identifying and addressing gaps in knowledge and research on safe and effective therapies for pregnant and lactating persons, including the development of such therapies and the collaboration on and coordination of such activities.

The task force developed 15 recommendations based on information gleaned during four open meetings and a request for public comments. The recommendations were submitted in the PRGLAC Report to the HHS Secretary and Congress in September 2018. The report recommended that pregnant and lactating persons be included in the clinical research agenda. The task force published a PRGLAC Implementation Plan in August 2020. A comprehensive review of research conducted for the task force deliberations clearly showed the extremely limited information available on medication use in pregnancy and lactation. Evidence-based answers are required for pregnant and lactating persons and their clinicians to make fully informed choices based on the risks and benefits of medicating or not medicating conditions during pregnancy and lactation. The provision of clinical data is essential to increasing the quantity, quality, and timeliness of research on safety and efficacy of therapeutic products used by pregnant, postpartum, and lactating persons.

Most women use at least one medication during pregnancy and the postpartum period. Many women who become pregnant or are lactating already have chronic conditions needing treatment, in addition to conditions that may arise as a result of pregnancy or lactation. Consequently, because so few studies have been conducted, some prioritization is necessary to determine which drugs, vaccines, and dietary supplements should be studied first.

Information Requested

The NICHD seeks information and actionable recommendations on research gaps and needs as potential priorities for drugs, vaccines, and dietary supplements used by pregnant, postpartum, or lactating persons.

Comments are strongly encouraged to address challenges and knowledge gaps around drugs, vaccines, or dietary supplements used during pregnancy, the postpartum period, or lactation on